Chiome Bioscience: Announcements of the exercise of large amounts of subscription rights (with exercise price adjustment clause) in the 21st period.
Chiome Bioscience: Supplementary information on the financial results for the second quarter of the period ending December 2024.
Chiome Bioscience: Non-consolidated performance for the 6 months ending on June 30th, 2024 (Japanese accounting standards).
Chiome Bioscience: Announcements of individual stocks regarding patent assessments in Japan for the combination of humanized DLK-1 antibody and lenvatinib.
Chiome Bioscience: Announcements of subscription rights (with exercise price adjustment clause) for the 20th and 21st month exercise status
Chiome Bioscience: Initiation of phase I clinical trial of therapeutic antibody drug conjugate ADCT-701.
Chiome Bioscience: Announcements of individual stocks: Start of administration in Phase 1 clinical trials of ADC therapy for cancer treatment ADCT-701.
Chiome Bioscience: Announcements of individual stock: Business partnership about the development of biosimilar pharmaceuticals with KidsWell Bio Co., Ltd.
Chiome Bioscience: Notice regarding the monthly exercise status of the 20th Stock Acquisition Rights (with exercise price amendment clause)
Chiome Bioscience: Presentation of research results using Chiome's antibodies at the 67th Annual Meeting of the Japanese Society of Nephrology
Chiome Bioscience: Announcement of research results using our antibodies at the 67th Annual Meeting of the Japanese Society of Nephrology
CHIOME BIOSCIENCE: Supplementary information on financial results for the 1st quarter of the fiscal year ending December 24
CHIOME BIOSCIENCE: Unconsolidated financial results for the three months ended March 31, 2024 (Japanese Accounting Standards)
CHIOME BIOSCIENCE: Notice Concerning the Recording of Non-Operating Profit
CHIOME BIOSCIENCE: Notice regarding the monthly exercise status of the 20th Stock Acquisition Rights (with exercise price amendment clause)
CHIOME BIOSCIENCE: Notice Concerning Mass Exercise of the 20th Stock Acquisition Rights (with Exercise Price Amendment Clauses)
Chiom Bioscience: Notice Concerning the Monthly Exercise Status of the 20th Stock Acquisition Rights (with Exercise Price Amendment Clauses)
Chiome Biosciences: End of license agreement with ADC Therapeutics
Chiom Biosciences: Notice of termination of license agreement with ADC Therapeutics due to transition of ADCT-701 clinical trial subjects to NCI
Chiome Biosciences: Notice regarding patent assessment in China relating to PCDC, a candidate antibody for cancer treatment
No Data